Malignant lesions in the ventral prostate of alloxan-induced diabetic rats

International Journal of Experimental Pathology

Volumn 89, Issue 4, 2008, Pages 276-283

  Ribeiro, Daniele Lisboa ^b   Marques, Silvio Fernando Guideti ^a   Alberti, Sandra ^a   Spadella, César Tadeu ^a   Manzato, Antônio José ^a   Taboga, Sebastião Roberto ^a   Dizeyi, Nishtman ^c   Abrahamsson, Per Anders ^c   Góes, Rejane Maira ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alloxan; Diabetes; Inflammation; Intra epithelial neoplasia; Prostate atrophy

Indexed keywords

ALLOXAN; ANDROGEN; INSULIN; PROTEIN BCL 2; TESTOSTERONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASEMENT MEMBRANE; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; IMMUNOHISTOCHEMISTRY; MALE; MORPHOLOGY; NONHUMAN; ORGAN WEIGHT; PRECANCER; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE VENTRAL LOBE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATITIS; RAT; STEREOLOGY; TESTOSTERONE BLOOD LEVEL;

ADENOCARCINOMA; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; IMMUNOHISTOCHEMISTRY; MALE; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; PROSTATITIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RATS, WISTAR; TENASCIN; TESTOSTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 47649105820     PISSN: 09599673     EISSN: 13652613     Source Type: Journal    
DOI: 10.1111/j.1365-2613.2008.00591.x     Document Type: Article

References (33)

1. Barros R.P.A., Machado U.F., Gustafsson J.A. (2006) Estrogens receptors: new players in diabetes mellitus. Trend. Mol. Med. 12, 425 431.
2. Bilic N. (1975) The mechanism of alloxan toxicity: na indication for alloxan complexes in tissues and alloxan inhibition of 4-acetamido-4'- isothioeyanato-stilbene-2,2'-disulphonic acid (SITS) binding for the liver call membrane. Diabetologia 11, 39 43.
3. Cagnon V.H.A., Camargo A.M., Rosa R.M., Fabiani C.R., Padovani C.R., Martinez F.E. (2000) Ultrastructure study of the ventral lobe of the prostate of mice with streptozotocin induced diabetes (C57bl/6j). Tissue Cell 32, 275 283.
4. Calton B.A., Chang S.C., Wright M.E. et al. (2007) History of diabetes mellitus and subsequent prostate cancer risk in the NIH-AARP Diet and Health Study. Cancer Causes Control 18, 493 503.
5. Calvet H.M. Yoshikawa T.T. (2001) Infections in diabetes. Infect. Dis. Clin. North Am. 15, 407 421.
6. Cleutjens C.B.J.M. (1997) Both androgen receptor and glucocorticoid receptor are able to induce prostate-specifc antigen expression, but differ in their growth-stimulating properties of LNCaP cells. Endocrinology 138, 5293 5300.
7. De Marzo A.M., Meeker A.K., Zha S. et al. (2003) Human prostate cancer precursors and pathobiology. Urology 62, 55 60.
8. De Marzo A.M., Platz E.A., Sutcliffe S. et al. (2007) Inflammation in prostate carcinogenesis. Nature 7, 256 269.
9. Faith D., Han S., Lee D.K. et al. (2005) p16 up-regulated proliferative inflammatory atrophy of the prostate. Prostate 65, 73 82.
10. Goes R.M., Zanetoni C., Tomisso T.C., Ribeiro D.L., Taboga S.R. (2007) Surgical and chemical castration induce differential histological response in prostate lobes of mongolian gerbil. Micron 38, 231 236.
11. Harmam A.W. Fischer L.J. (1982) Alloxan toxicity in isolated rat hepatocytes and protection by sugars. Biochem. Pharmacol. 31, 3731 3736.
12. Huang J., Lin T., Chang D., Lin S., Ying S. (2003) Truncated Bcl-2, a potential pre-metastatic marker in prostate cancer. Biochem. Biophys. Res. Comm. 306, 912 917.
13. Ilic M., Vlajinac H., Marinkovic J. (1996) Case control study of risk factors for prostate cancer. Br. J. Cancer 74, 1682 1686.
14. Karainov M., Todonova K., Kuzmanov A., Hayrabedyan S. (2007) Quantitative immunohistochemical detection of the molecular expression patterns in proliferative inflammatory atrophy. J. Mol. Hist. 38, 1 11.
15. Kodama Y., Ozaki K., Sano T., Matsuura T., Akagi H., Narama I. (2006) Induction of squamous cell carcinoma of forestomach in diabetic rats by single alloxan treatment. Cancer Sci. 97, 1023 1030.
16. Lerco M.M., Spadella C.T., Machado J.L.M., Schellini A.S., Padovani C.R. (2003) Caracterização de um modelo experimental de Diabetes Mellitus, induzido pela aloxana em ratos. Estudo clínico e laboratorial. Acta Cirúrgica Brasileira 18, 132 142.
17. Mackey Tj., Borkowski A., Amin P., Jacobs Sc., Kyprianou N. (1998) Bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urology 52, 1085.
18. Michel M.C., Mehlburger L., Schumacher H., Bressel H.U., Goepel M. (2000) Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia. J. Urol. 163, 1725 1729.
19. Nelson W.G., de Marzo A.M., Isaacs W.B. (2003) Prostate cancer. N. Engl. J. Med. 349, 366 381.
20. Oliveira S.M., Vilamaior P.S.L., Corradi L.S., Góes R.M., Taboga S.R. (2007) Cellular and extracellular behavior in the gerbil (Meriones unguiculatus) ventral prostate following different types of castration and the consequences of testosterone replacement. Cell Biol. Int. 31, 235 24.
21. Palapattu G.S., Suteliffe S., Bastian P.J. et al. (2004) Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 26, 1170 1181.
22. Ribeiro D.L., Caldeira E.J., Candido E.M., Manzato A.J., Taboga S.R., Cagnon V.A. (2006) Prostatic stromal microenvironment and experimental diabetes. Eur. J. Histochem. 50, 51 60.
23. Robbins S.L. (1989) Doenças Sistêmicas. In : Diabetes Mellitus. Patologia Estrutural e Funcional, pp. 238 250 (editor S.L. Robbins Canadá : W.B. Sounders Company.
24. Shappel S.B., Thomas G.V., Roberts R.L. et al. (2004) Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res. 61, 2270 2305.
25. Soudamani S., Yuvaraj S., Malini T., Balasubramanian K. (2005) Experimental diabetes has adverse effects on the differentiation os ventral prostate during sexual maturation of rats. Anat. Rec. A Discov. Mol. Cell. Evol. Biol. 287, 1281 1289.
26. Tomas D., Kruslin B., Rogatsch H., Schäfer G., Belicza M., Mikuz G. (2007) Different types of atrophy in the prostate with and without adenocarcinoma. Eur. Urol. 51, 98 104.
27. Wang W., Bergh A., Damber J.E. (2004) Chronic inflammation in benign prostate hyperplasia is associated with focal up-regulation of COX-2, Bcl-2 and cell proliferation in the glandular epithelium. The Prostate 61, 60 72.
28. Weeks I., Woodhead J.S. (1984) Chemiluminescence immunoassays. J. Clin. Immunoassays 7, 82 89.
29. Weibel E.R. (1963) Principles and methods for the morphometric study of the lung and other organs. Lab. Invest. 12, 131 155.
30. Weiderpass E., Ye W., Vainio H., Kaaks R., Adami H.-O. (2002) Reduced risk of prostate cancer among patients with diabetes mellitus. Int. J. Cancer 102, 258 261.
31. Will J.C., Vinicor F., Calle E.E. (1999) Is diabetes mellitus associated with prostate cancer incidence and survival? Epidemiology 10, 313 318.
32. Yono M., Pouresmail M., Takahashi W., Flanagan J.F., Weiss R.M., Latifpour J. (2005) Effect of insulin treatment on tissue size of the genitourinary tract in BB rats with spontaneously developed and streptozotocin-induced diabetes. Naunyn-Schmiedeberg's Arch Pharmacol 372, 251 255.
33. Yoshino T., Shiina H., Urakami S. et al. (2006) Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin. Cancer Res. 12, 6116 6124.